Evaluation of a new transperineal ultrasound probe for inter-fraction image-guidance for definitive and post-operative prostate cancer radiotherapy.

PURPOSE - The aim of this study was to evaluate a new system based on transperineal ultrasound (TP-US) acquisitions for prostate and post-prostatectomy pre-treatment positioning by comparing this device to cone-beam computed tomography (CBCT).

METHODS - The differences between CBCT/CT and TP-US/TP-US registrations were analyzed on 427 and 453 sessions for 13 prostate and 14 post-prostatectomy patients, respectively. The inter-operator variability (IOV) of the registration process, and the impact and variability of the probe pressure were also evaluated.

RESULTS - CBCT and TP-US shift agreements at ± 5 mm were 76. 6%, 95. 1%, 96. 3% and 90. 3%, 85. 0%, 97. 6% in anterior-posterior, superior-inferior and left-right directions, for prostate and post-prostatectomy patients, respectively. IOV values were similar between the 2 modalities. Displacements above 5 mm due to strong pressures were observed on both localizations, but such pressures were rarely reproduced during treatment courses.

CONCLUSIONS - High concordance between CBCT/CT and TP-US/TP-US localization of prostates or prostatic beds was found in this study. TP-US based prepositioning is a feasible method to ensure accurate treatment delivery, and represents an attractive alternative to invasive and/or irradiating imaging modalities.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB). 2016 Feb 02 [Epub ahead of print]

Marie Fargier-Voiron, Benoît Presles, Pascal Pommier, Alexandre Munoz, Simon Rit, David Sarrut, Marie-Claude Biston

CREATIS, INSA, Université de Lyon, CNRS UMR5220, Inserm U1044, Lyon F-69622, France. , CREATIS, INSA, Université de Lyon, CNRS UMR5220, Inserm U1044, Lyon F-69622, France. , Léon Bérard Cancer Center, University of Lyon, Lyon F-69373, France. , Léon Bérard Cancer Center, University of Lyon, Lyon F-69373, France. , CREATIS, INSA, Université de Lyon, CNRS UMR5220, Inserm U1044, Lyon F-69622, France. , CREATIS, INSA, Université de Lyon, CNRS UMR5220, Inserm U1044, Lyon F-69622, France; Léon Bérard Cancer Center, University of Lyon, Lyon F-69373, France. , CREATIS, INSA, Université de Lyon, CNRS UMR5220, Inserm U1044, Lyon F-69622, France; Léon Bérard Cancer Center, University of Lyon, Lyon F-69373, France. 

PubMed